These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37127565)

  • 1. Clinical significance of serum-derived exosomal PD-L1 expression in patients with advanced pancreatic cancer.
    Park SJ; Park JY; Shin K; Hong TH; Lee M; Kim Y; Kim IH
    BMC Cancer; 2023 May; 23(1):389. PubMed ID: 37127565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy.
    Shin K; Kim J; Park SJ; Lee MA; Park JM; Choi MG; Kang D; Song KY; Lee HH; Seo HS; Lee SH; Kim B; Kim O; Park J; Kang N; Kim IH
    Sci Rep; 2023 Apr; 13(1):6952. PubMed ID: 37117200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating PD-L1 is associated with T cell infiltration and predicts prognosis in patients with CRLM following hepatic resection.
    Chen X; Du Z; Huang M; Wang D; Fong WP; Liang J; Fan L; Wang Y; Yang H; Chen Z; Hu M; Xu R; Li Y
    Cancer Immunol Immunother; 2022 Mar; 71(3):661-674. PubMed ID: 34322779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of circulating exosomal PD-L1 and soluble PD-L1 in extranodal NK/T-cell lymphoma, nasal-type.
    Li JW; Wei P; Guo Y; Shi D; Yu BH; Su YF; Li XQ; Zhou XY
    Am J Cancer Res; 2020; 10(12):4498-4512. PubMed ID: 33415014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantification-Promoted Discovery of Glycosylated Exosomal PD-L1 as a Potential Tumor Biomarker.
    Zhu L; Xu Y; Kang S; Lin B; Zhang C; You Z; Lin H; Yang C; Song Y
    Small Methods; 2022 Sep; 6(9):e2200549. PubMed ID: 35810463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exosomal PD-L1 in cancer and other fields: recent advances and perspectives.
    Lu MM; Yang Y
    Front Immunol; 2024; 15():1395332. PubMed ID: 38726017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients.
    Yang Q; Chen M; Gu J; Niu K; Zhao X; Zheng L; Xu Z; Yu Y; Li F; Meng L; Chen Z; Zhuo W; Zhang L; Sun J
    Front Immunol; 2021; 12():665133. PubMed ID: 33936103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coaxial dual-path electrochemical biosensing and logic strategy-based detection of lung cancer-derived exosomal PD-L1.
    Liu J; Liu Z; Zhao C; Jiao Y; Li B; Shi J; Chen Z; Zhang Z
    Nanoscale; 2024 May; 16(18):8950-8959. PubMed ID: 38630023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exosomal PD-L1 and N-cadherin predict pulmonary metastasis progression for osteosarcoma patients.
    Wang J; Zhang H; Sun X; Wang X; Ren T; Huang Y; Zhang R; Zheng B; Guo W
    J Nanobiotechnology; 2020 Oct; 18(1):151. PubMed ID: 33092576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. c-Met and PD-L1 on Circulating Exosomes as Diagnostic and Prognostic Markers for Pancreatic Cancer.
    Lux A; Kahlert C; Grützmann R; Pilarsky C
    Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31284422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homogeneous, Low-volume, Efficient, and Sensitive Quantitation of Circulating Exosomal PD-L1 for Cancer Diagnosis and Immunotherapy Response Prediction.
    Huang M; Yang J; Wang T; Song J; Xia J; Wu L; Wang W; Wu Q; Zhu Z; Song Y; Yang C
    Angew Chem Int Ed Engl; 2020 Mar; 59(12):4800-4805. PubMed ID: 31912940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of dendritic cells on immune function regulated by programmed cell death-1/programmed cell death-ligand 1 in sepsis].
    Wang Z; Xie Z; Zhao Y; Bu T; Yu A; Wang S
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2021 Sep; 33(9):1032-1039. PubMed ID: 34839857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between exosomal PD-L1 and prognosis in patients with cancer: a systematic review and meta-analysis.
    Huang L; He Q; Liu L; Huang J; Chang F
    Clin Transl Oncol; 2024 Aug; ():. PubMed ID: 39177941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer.
    Niu M; Liu Y; Yi M; Jiao D; Wu K
    Front Immunol; 2022; 13():827921. PubMed ID: 35386715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison to established serum tumor markers.
    Dorman K; Gerckens M; Kruger S; Krueger K; Mayer Z; Rupp A; Zhang D; Weiss L; Westphalen CB; Haas M; Guenther M; Ormanns S; Klawonn F; Werner J; von Bergwelt-Baildon M; Heinemann V; Boeck S; Holdenrieder S
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2463-2474. PubMed ID: 35737090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis.
    Gao HL; Liu L; Qi ZH; Xu HX; Wang WQ; Wu CT; Zhang SR; Xu JZ; Ni QX; Yu XJ
    Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):95-100. PubMed ID: 29576277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients.
    Li C; Li C; Zhi C; Liang W; Wang X; Chen X; Lv T; Shen Q; Song Y; Lin D; Liu H
    J Transl Med; 2019 Oct; 17(1):355. PubMed ID: 31665020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ExoPD-L1: an assistant for tumor progression and potential diagnostic marker.
    Hu R; Jahan MS; Tang L
    Front Oncol; 2023; 13():1194180. PubMed ID: 37736550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression.
    Shigemori T; Toiyama Y; Okugawa Y; Yamamoto A; Yin C; Narumi A; Ichikawa T; Ide S; Shimura T; Fujikawa H; Yasuda H; Hiro J; Yoshiyama S; Ohi M; Araki T; Kusunoki M
    Ann Surg Oncol; 2019 Mar; 26(3):876-883. PubMed ID: 30565045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.